2023
Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer.
Peng C, Saffo S, Shusterman M, Becker D, Berlin J, Oberstein P, Nagar A, Yu S. Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer. Journal Of Clinical Oncology 2023, 41: 59-59. DOI: 10.1200/jco.2023.41.4_suppl.59.Peer-Reviewed Original ResearchMetastatic colorectal cancerOverall survivalECOG scoreColorectal cancerUnivariable Cox proportional hazards modelsFirst-line treatment regimensCox proportional hazards modelHigh-risk comorbiditiesHigher ECOG scoreRole of bolusMulticenter cohort studyOverall survival benefitRisk of deathLimited functional statusCombination drug regimenProportional hazards modelUse of bolusPropensity-score matchingAdjuvant settingBaseline creatinineFlatiron HealthMedian followCohort studyCreatinine levelsDrug regimen
2022
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study
Ozonoff A, Schaenman J, Jayavelu ND, Milliren CE, Calfee CS, Cairns CB, Kraft M, Baden LR, Shaw AC, Krammer F, van Bakel H, Esserman DA, Liu S, Sesma AF, Simon V, Hafler DA, Montgomery RR, Kleinstein SH, Levy O, Bime C, Haddad EK, Erle DJ, Pulendran B, Nadeau KC, Davis MM, Hough CL, Messer WB, Higuita NIA, Metcalf JP, Atkinson MA, Brakenridge SC, Corry D, Kheradmand F, Ehrlich LIR, Melamed E, McComsey GA, Sekaly R, Diray-Arce J, Peters B, Augustine AD, Reed EF, Altman MC, Becker PM, Rouphael N, Ozonoff A, Schaenman J, Jayavelu N, Milliren C, Calfee C, Cairns C, Kraft M, Baden L, Shaw A, Krammer F, van Bakel H, Esserman D, Liu S, Sesma A, Simon V, Hafler D, Montgomery R, Kleinstein S, Levy O, Bime C, Haddad E, Erle D, Pulendran B, Nadeau K, Davis M, Hough C, Messer W, Higuita N, Metcalf J, Atkinson M, Brakenridge S, Corry D, Kheradmand F, Ehrlich L, Melamed E, McComsey G, Sekaly R, Diray-Arce J, Peters B, Augustine A, Reed E, McEnaney K, Barton B, Lentucci C, Saluvan M, Chang A, Hoch A, Albert M, Shaheen T, Kho A, Thomas S, Chen J, Murphy M, Cooney M, Presnell S, Fragiadakis G, Patel R, Guan L, Gygi J, Pawar S, Brito A, Khalil Z, Maguire C, Fourati S, Overton J, Vita R, Westendorf K, Salehi-Rad R, Leligdowicz A, Matthay M, Singer J, Kangelaris K, Hendrickson C, Krummel M, Langelier C, Woodruff P, Powell D, Kim J, Simmons B, Goonewardene I, Smith C, Martens M, Mosier J, Kimura H, Sherman A, Walsh S, Issa N, Dela Cruz C, Farhadian S, Iwasaki A, Ko A, Chinthrajah S, Ahuja N, Rogers A, Artandi M, Siegel S, Lu Z, Drevets D, Brown B, Anderson M, Guirgis F, Thyagarajan R, Rousseau J, Wylie D, Busch J, Gandhi S, Triplett T, Yendewa G, Giddings O, Anderson E, Mehta A, Sevransky J, Khor B, Rahman A, Stadlbauer D, Dutta J, Xie H, Kim-Schulze S, Gonzalez-Reiche A, van de Guchte A, Farrugia K, Khan Z, Maecker H, Elashoff D, Brook J, Ramires-Sanchez E, Llamas M, Rivera A, Perdomo C, Ward D, Magyar C, Fulcher J, Abe-Jones Y, Asthana S, Beagle A, Bhide S, Carrillo S, Chak S, Fragiadakis G, Ghale R, Gonzalez A, Jauregui A, Jones N, Lea T, Lee D, Lota R, Milush J, Nguyen V, Pierce L, Prasad P, Rao A, Samad B, Shaw C, Sigman A, Sinha P, Ward A, Willmore A, Zhan J, Rashid S, Rodriguez N, Tang K, Altamirano L, Betancourt L, Curiel C, Sutter N, Paz M, Tietje-Ulrich G, Leroux C, Connors J, Bernui M, Kutzler M, Edwards C, Lee E, Lin E, Croen B, Semenza N, Rogowski B, Melnyk N, Woloszczuk K, Cusimano G, Bell M, Furukawa S, McLin R, Marrero P, Sheidy J, Tegos G, Nagle C, Mege N, Ulring K, Seyfert-Margolis V, Conway M, Francisco D, Molzahn A, Erickson H, Wilson C, Schunk R, Sierra B, Hughes T, Smolen K, Desjardins M, van Haren S, Mitre X, Cauley J, Li X, Tong A, Evans B, Montesano C, Licona J, Krauss J, Chang J, Izaguirre N, Chaudhary O, Coppi A, Fournier J, Mohanty S, Muenker M, Nelson A, Raddassi K, Rainone M, Ruff W, Salahuddin S, Schulz W, Vijayakumar P, Wang H, Wunder E, Young H, Zhao Y, Saksena M, Altman D, Kojic E, Srivastava K, Eaker L, Bermúdez-González M, Beach K, Sominsky L, Azad A, Carreño J, Singh G, Raskin A, Tcheou J, Bielak D, Kawabata H, Mulder L, Kleiner G, Lee A, Do Do E, Fernandes A, Manohar M, Hagan T, Blish C, Din H, Roque J, Yang S, Brunton A, Sullivan P, Strnad M, Lyski Z, Coulter F, Booth J, Sinko L, Moldawer L, Borresen B, Roth-Manning B, Song L, Nelson E, Lewis-Smith M, Smith J, Tipan P, Siles N, Bazzi S, Geltman J, Hurley K, Gabriele G, Sieg S, Vaysman T, Bristow L, Hussaini L, Hellmeister K, Samaha H, Cheng A, Spainhour C, Scherer E, Johnson B, Bechnak A, Ciric C, Hewitt L, Carter E, Mcnair N, Panganiban B, Huerta C, Usher J, Ribeiro S, Altman M, Becker P, Rouphael N. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study. EBioMedicine 2022, 83: 104208. PMID: 35952496, PMCID: PMC9359694, DOI: 10.1016/j.ebiom.2022.104208.Peer-Reviewed Original ResearchConceptsRisk factorsRadiographic findingsFemale sexDisease severityHospitalized COVID-19 patientsSARS-CoV-2 antibodiesSARS-CoV-2 PCRLong COVID-19Presence of infiltratesInvasive mechanical ventilationCharacteristics of patientsOnly female sexViral load levelsClinical laboratory valuesCOVID-19 cohortMultivariable logistic regressionCOVID-19 patientsCoronavirus disease 2019PCR cycle thresholdCOVID-19Baseline creatinineBaseline lymphopeniaMedian ageOverall mortalityProlonged hospitalizationResolving icteric interference by a novel photoisomerization device: Bilibox
Vera MA, Koch CD, El-Khoury JM. Resolving icteric interference by a novel photoisomerization device: Bilibox. Clinical Biochemistry 2022, 115: 112-115. PMID: 35882276, DOI: 10.1016/j.clinbiochem.2022.07.004.Peer-Reviewed Original ResearchConceptsDirect bilirubinIcteric interferenceAforementioned analytesChemical reactivityPhotoisomerizationRoutine laboratory testingEndogenous interferencesBilirubin elevationBaseline creatinineAssay reagentsLaboratory testingDilutional methodMin of treatmentCreatinineEnzymatic creatinine assayIcterusBilirubinChemistry testingClinical samplesCreatinine assaysHeparin vacutainersTreatmentAnalytesIctericRepeat measurements
2021
Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure
Fudim M, Spates T, Sun JL, Kittipibul V, Testani JM, Starling RC, Tang WHW, Hernandez AF, Felker GM, O'Connor CM, Mentz RJ. Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. American Heart Journal 2021, 239: 110-119. PMID: 34052212, DOI: 10.1016/j.ahj.2021.05.011.Peer-Reviewed Original ResearchMeSH KeywordsCreatinineDiureticsDrug MonitoringFemaleFurosemideHeart FailureHospitalizationHumansInfusions, IntravenousInjections, IntravenousMaleMiddle AgedMortalityNatriuretic Peptide, BrainOutcome and Process Assessment, Health CarePatient ReadmissionPeptide FragmentsTime-to-TreatmentUnited StatesConceptsIntermittent bolus administrationAcute heart failureDecompensated heart failureHeart failurePost-discharge outcomesDiuretic strategyDay mortalityBolus administrationDays/dischargeHigher baseline creatinineIntermittent bolus groupTotal urine outputBaseline creatinineDiuretic regimenHigh NTproBNPCause mortalityHF readmissionHF rehospitalizationHospital outcomesBaseline characteristicsCardiovascular mortalityIn-HospitalRenal functionBolus groupContinuous therapy#18: Brincidofovir for the Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid-organ Transplant Recipients
Londeree J, Garro R, Romero R, George R, Winterberg P, Liverman R, Serluco A, Shin S, Yildirim I. #18: Brincidofovir for the Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid-organ Transplant Recipients. Journal Of The Pediatric Infectious Diseases Society 2021, 10: s3-s3. DOI: 10.1093/jpids/piaa170.008.Peer-Reviewed Original ResearchPediatric SOT patientsAcute kidney injuryHAdV infectionSolid organ transplantationSOT patientsSevere diseaseResolution of AKIPediatric solid organ transplant recipientsSolid organ transplant recipientsAntiviral treatment optionsInvestigational antiviral drugsPediatric transplant centersBaseline clinical characteristicsDays of therapyMainstay of treatmentResolution of symptomsSubset of patientsHuman adenovirus infectionHAdV viral loadsAdenovirus viremiaBaseline creatinineGraft involvementGraft lossHAdV viremiaReduced immunosuppression
2018
Outcomes of Adult Intestinal Transplant Recipients Requiring Dialysis and Renal Transplantation
Puttarajappa C, Hariharan S, Humar A, Paliwal Y, Gao X, Cruz R, Ganoza A, Landsittel D, Bhattarai M, Sogawa H. Outcomes of Adult Intestinal Transplant Recipients Requiring Dialysis and Renal Transplantation. Transplantation Direct 2018, 4: e377. PMID: 30255137, PMCID: PMC6092176, DOI: 10.1097/txd.0000000000000815.Peer-Reviewed Original ResearchEnd-stage renal diseaseIntestinal transplant recipientsRenal transplantationIntestinal transplantationTransplant recipientsFunctioning graftPatient survivalSurgical techniqueAdult intestinal transplant recipientsAdult intestinal transplantationHigher baseline creatinineMedian Follow-UpMedian patient survivalAssociated with increased mortalityEnd-stage renal disease riskLong-term dialysisIncreased ESRD riskBaseline creatinineReceiving RTInfectious complicationsGraft lossRenal failureFollow-upRenal diseaseDialysis initiationMembranous nephropathy with light chain restricted deposits
Ramachandran R, Inamdar N, Bharati J, Yadav A, Kumar A, Prakash G, Nada R, Rathi M, Kohli H, Gupta K, Jha V. Membranous nephropathy with light chain restricted deposits. Nephrology 2018, 23: 791-796. PMID: 29633425, DOI: 10.1111/nep.13268.Peer-Reviewed Original ResearchConceptsMonths of follow-upMembranous nephropathySerum creatinineMonoclonal depositsFollow-upM-type phospholipase A2 receptorElevated free light chainsFree light chain ratioElevated baseline creatininePLA2R-positive MNTreated with rituximabEfficacy of conventional therapiesPhospholipase A2 receptorLight chain ratioFree light chainsPLA2R positivityBaseline creatinineLymphoproliferative disordersPersistent proteinuriaA2 receptorsClinical entityCyclical cyclophosphamideConventional therapyNon-malignantRemission
2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical And Experimental Rheumatology 2016, 35 Suppl 106: 106-113. PMID: 27908301.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideNT-proBNP levelsPg/mLSSc-PHNT-proBNPPulmonary hypertensionSSc patientsSystemic sclerosisNatriuretic peptideBaseline B-type natriuretic peptideMedian B-type natriuretic peptideSystemic sclerosis-associated pulmonary hypertensionMulticenter prospective cohortNT-proBNP groupNatriuretic peptide levelsRight ventricular dysfunctionPredictors of mortalityPulmonary arterial hypertensionPredictors of progressionAssessment of patientsBaseline creatinineSSc-PAHArterial hypertensionPAH patientsVentricular dysfunction
2013
The impact of documentation of severe acute kidney injury on mortality
Wilson FP, Bansal AD, Jasti SK, Lin JJ, Shashaty MG, Berns JS, Feldman HI, Fuchs BD. The impact of documentation of severe acute kidney injury on mortality. Clinical Nephrology 2013, 80: 417-425. PMID: 24075024, PMCID: PMC4018223, DOI: 10.5414/cn108072.Peer-Reviewed Original ResearchConceptsAcute kidney injuryBaseline creatinineKidney injuryHigher Sequential Organ Failure Assessment scoreDocumentation of AKIRecognition of AKISequential Organ Failure Assessment scoreAngiotensin receptor blocker medicationHospital acute kidney injuryOrgan Failure Assessment scoreSevere acute kidney injuryHigher baseline creatinineHigher peak creatinineRetrospective cohort studyImproved clinical outcomesUniversity Health SystemSeverity of diseaseNephrology consultationPeak creatinineRapid discontinuationCohort studyImproved survivalClinical outcomesIllness severityKidney disease
2012
Predictors of Death and Dialysis in Severe AKI: The UPHS-AKI Cohort
Wilson FP, Yang W, Feldman HI. Predictors of Death and Dialysis in Severe AKI: The UPHS-AKI Cohort. Clinical Journal Of The American Society Of Nephrology 2012, 8: 527-537. PMID: 23258795, PMCID: PMC3613955, DOI: 10.2215/cjn.06450612.Peer-Reviewed Original ResearchConceptsSevere AKIC-indexIntensive care unit locationPredictors of deathEffective risk stratificationEndpoint of deathMore effective therapeutic interventionsHigh-risk subgroupsHarrell's C-indexLower overall mortalityProportional hazards modelEffective therapeutic interventionsPennsylvania Health SystemBaseline creatinineHospital AKIPressor medicationsSerum creatinineClinical factorsDerivation cohortHigher creatinineHospital admissionOverall mortalityLiver diseaseRisk stratificationValidation cohort
2008
Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus
Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA. Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. The American Journal Of Cardiology 2008, 101: 925-929. PMID: 18359309, DOI: 10.1016/j.amjcard.2007.11.037.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionRenal dysfunctionRenal functionMyocardial infarctionCV outcomesDiabetes mellitusHigh-risk acute myocardial infarctionCox proportional modelingAdverse CV outcomesComposite cardiovascular eventsComposite end pointIndependent risk factorRenal Disease equationGlomerular filtration rateReduced renal functionBaseline creatinineCV eventsMean eGFRCardiovascular eventsCV diseaseCV riskVentricular dysfunctionCardiovascular riskHeart failureOverall mortality
2006
Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction
Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD, Investigators F. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. Journal Of The American Society Of Nephrology 2006, 17: 2886-2891. PMID: 16928807, DOI: 10.1681/asn.2006010063.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionCaptopril groupCardiovascular riskRenal functionSerum creatininePotent independent risk factorVentricular Enlargement (SAVE) trialBaseline renal functionHeart failure populationComposite end pointIndependent risk factorSerum creatinine measurementsBaseline creatinineCardiovascular deathCardiovascular morbidityPlacebo groupRenal dysfunctionSystolic dysfunctionVentricular dysfunctionAdverse eventsPrognostic importanceFailure populationTherapeutic choiceRisk factors
2003
Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure?
Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM. Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure? Journal Of Cardiac Failure 2003, 9: 13-25. PMID: 12612868, DOI: 10.1054/jcaf.2003.3.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCohort StudiesConnecticutCreatinineFemaleFollow-Up StudiesHeart FailureHospitalizationHumansKidney DiseasesKidney Function TestsMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsProspective StudiesRisk FactorsSensitivity and SpecificityStatistics as TopicStroke VolumeSurvival AnalysisConceptsCreatinine elevationRenal functionHeart failureAdverse outcomesRisk of deathNumber of patientsMagnitude of riskBaseline creatinineProspective cohortRisk factorsFunctional declineHigh riskPatientsCreatinineMortalityHospitalizationDeathDlImportant predictorRiskElevationMeaningful changeMaximum specificityOutcomesBetter definition
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply